CRASH-2
Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage
Paciente / Población Intervención / Exposición Comparación Desenlace
In 20,211 trauma patients with significant haemorrhage, tranexamic acid within 3 hours reduced all-cause death versus placebo.
N
20.211
Diseño
International RCT
Desenlace
In-hospital all-cause mortality at 4 weeks
Relevancia
1
Resultado14.5% vs 16.0% (RR 0.91; p=0.0035); benefit only ≤3 h from injury.
CRASH-2 Trial Collaborators. Lancet. 2010;376(9734):23-32. 10.1016/S0140-6736(10)60835-5
Discusión y crítica
Cheap, available, time-critical; the central trauma drug since 2010.